306 related articles for article (PubMed ID: 33086019)
1. An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications.
Karanam NK; Story MD
Int J Radiat Biol; 2021; 97(8):1044-1054. PubMed ID: 33086019
[TBL] [Abstract][Full Text] [Related]
2. Tumor treating fields: a comprehensive overview of the underlying molecular mechanism.
Hong P; Kudulaiti N; Wu S; Nie J; Zhuang D
Expert Rev Mol Diagn; 2022 Jan; 22(1):19-28. PubMed ID: 34883030
[TBL] [Abstract][Full Text] [Related]
3. A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights.
Li X; Liu K; Xing L; Rubinsky B
Radiol Oncol; 2023 Sep; 57(3):279-291. PubMed ID: 37665740
[TBL] [Abstract][Full Text] [Related]
4. Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies.
Wang Y; Pandey M; Ballo MT
Oncologist; 2019 Dec; 24(12):e1426-e1436. PubMed ID: 31444292
[TBL] [Abstract][Full Text] [Related]
5. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines.
Karanam NK; Srinivasan K; Ding L; Sishc B; Saha D; Story MD
Cell Death Dis; 2017 Mar; 8(3):e2711. PubMed ID: 28358361
[TBL] [Abstract][Full Text] [Related]
6. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.
Mumblat H; Martinez-Conde A; Braten O; Munster M; Dor-On E; Schneiderman RS; Porat Y; Voloshin T; Davidi S; Blatt R; Shteingauz A; Tempel-Brami C; Zeevi E; Lajterer C; Shmueli Y; Danilov S; Haber A; Giladi M; Weinberg U; Kinzel A; Palti Y
Lung Cancer; 2021 Oct; 160():99-110. PubMed ID: 34482104
[TBL] [Abstract][Full Text] [Related]
7. Tumor treating fields: narrative review of a promising treatment modality for cancer.
Kutuk T; Atak E; La Rosa A; Kotecha R; Mehta MP; Chuong MD
Chin Clin Oncol; 2023 Dec; 12(6):64. PubMed ID: 37953242
[TBL] [Abstract][Full Text] [Related]
8. Tumour treating fields therapy for glioblastoma: current advances and future directions.
Rominiyi O; Vanderlinden A; Clenton SJ; Bridgewater C; Al-Tamimi Y; Collis SJ
Br J Cancer; 2021 Feb; 124(4):697-709. PubMed ID: 33144698
[TBL] [Abstract][Full Text] [Related]
9. Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields]).
Shams S; Patel CB
J Mol Cell Biol; 2022 Dec; 14(8):. PubMed ID: 35973687
[TBL] [Abstract][Full Text] [Related]
10. Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy.
Pohling C; Nguyen H; Chang E; Schubert KE; Nie Y; Bashkirov V; Yamamoto V; Zeng Y; Stupp R; Schulte RW; Patel CB
Bioelectrochemistry; 2023 Feb; 149():108287. PubMed ID: 36306728
[TBL] [Abstract][Full Text] [Related]
11. An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma.
Swanson KD; Lok E; Wong ET
Curr Neurol Neurosci Rep; 2016 Jan; 16(1):8. PubMed ID: 26739692
[TBL] [Abstract][Full Text] [Related]
12. The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma.
Riley MM; San P; Lok E; Swanson KD; Wong ET
J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058901
[TBL] [Abstract][Full Text] [Related]
13. Tumor treating fields: a new frontier in cancer therapy.
Davies AM; Weinberg U; Palti Y
Ann N Y Acad Sci; 2013 Jul; 1291():86-95. PubMed ID: 23659608
[TBL] [Abstract][Full Text] [Related]
14. Treatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma.
Sarkari A; Korenfeld S; Deniz K; Ladner K; Wong P; Padmanabhan S; Vogel RI; Sherer LA; Courtemanche N; Steer C; Wainer-Katsir K; Lou E
Elife; 2023 Nov; 12():. PubMed ID: 37955637
[TBL] [Abstract][Full Text] [Related]
15. The schemes, mechanisms and molecular pathway changes of Tumor Treating Fields (TTFields) alone or in combination with radiotherapy and chemotherapy.
Tanzhu G; Chen L; Xiao G; Shi W; Peng H; Chen D; Zhou R
Cell Death Discov; 2022 Oct; 8(1):416. PubMed ID: 36220835
[TBL] [Abstract][Full Text] [Related]
16. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
Ornelas AS; Porter AB; Sharma A; Knox MG; Marks LA; Wingerchuk DM; O'Carroll CB
Neurologist; 2019 Mar; 24(2):71-73. PubMed ID: 30817495
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of tumor treating fields for malignant brain tumors.
Zhou Y; Xing X; Zhou J; Jiang H; Cen P; Jin C; Zhong Y; Zhou R; Wang J; Tian M; Zhang H
Cancer Rep (Hoboken); 2023 May; 6(5):e1813. PubMed ID: 36987739
[TBL] [Abstract][Full Text] [Related]
18. Technological Advances in the Treatment of Cancer: Combining Modalities to Optimize Outcomes.
Wong ET; Toms SA; Ahluwalia MS
Clin Adv Hematol Oncol; 2015 Nov; 13(11 Suppl 11):1-18. PubMed ID: 26862770
[TBL] [Abstract][Full Text] [Related]
19. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy.
Karanam NK; Ding L; Aroumougame A; Story MD
Transl Res; 2020 Mar; 217():33-46. PubMed ID: 31707040
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Treating Fields in Glioblastomas: Past, Present, and Future.
Guo X; Yang X; Wu J; Yang H; Li Y; Li J; Liu Q; Wu C; Xing H; Liu P; Wang Y; Hu C; Ma W
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]